CONSTANT LEVERAGE LONG - NOVO-NORDISK B | Market Closed - Euronext Paris 16:14:53 04/06/2024 BST | ||
| 0.725 EUR | +13.64% |
|
| Current month | +16.37% | ||
| 1 month | +187.70% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 04/06/24 | 0.725 | +13.64% |
| 03/06/24 | 0.638 | +2.41% |
| 31/05/24 | 0.623 | +7.60% |
| 30/05/24 | 0.579 | +7.42% |
| 29/05/24 | 0.539 | -7.55% |
Real-time Euronext Paris
Last update June 04, 2024 at 04:14 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| 7FLMB | |
| ISIN | NLBNPNL2IDZ4 |
| Date issued | 20/09/2023 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.625 € |
|---|---|
| Lowest since issue | 0.12 € |
| Spread | 0.018 € |
| Spread % | 2.62% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
936.2
DKK
Average target price
917.3
DKK
Spread / Average Target
-2.02%
- Stock Market
- Certificates
- 7FLMB Certificat
